Nath Bio-Genes (India) share news and announcements
NSE: NATHBIOGENBSE: 537291Agricultural Food & other ProductsSmall Cap
Last close ₹130.52up ₹0.15 (0.12%)BSE ₹127.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹130.37.
52-week range of traded prices to 23 Oct 2026
₹126.15Low, 30 Mar 2026₹204.00High, 30 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹248 Cr2,134th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 18 Sep 2026
- 6.8
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 8.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 4 May 2026
- 0.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 18 Sep 2026
- 5.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 18 Sep 2026
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 4 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,55672.5% delivered
Nath Bio-Genes (India) share news and announcements
347 announcements, routine notices left out, newest first. Page 3 of 7.
May 2023
23 May · Updates
Apr 2023
26 Apr · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.25 Apr · Corporate action
22 Apr · Board meeting
19 Apr · Analysts
Feb 2023
Dec 2022
7 Dec · General updates
Nov 2022
3 Nov · Related Party Transaction
Oct 2022
22 Oct · General updates
Aug 2022
Jul 2022
27 Jul · General updates
Jun 2022
11 Jun · Related Party Transaction
May 2022
Apr 2022
20 Apr · General updates
Feb 2022
Nov 2021
Oct 2021
30 Oct · Analysts
Aug 2021
Jul 2021